After several years of operating out of Ramat Gan, the company made a real estate leap by moving to Herzliya’s high-tech district - one of Israel’s most sought-after office hubs. The new ...

Ingelheim, Germany, May 6, 2025 – Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a ...

The collaboration combines Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilise challenging drug targets from Boehringer Ingelheim’s drug discovery programs to enable ...

“We are excited to collaborate with the innovative teams at Boehringer Ingelheim,” said Jens Frauenfeld, CEO of Salipro Biotech. “By combining our Salipro ® platform technology with Boehringer ...

Feb 25 (Reuters) - Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused cancer, both of which had previously ended with hung ...

Hyderabad, Telangana, India: Boehringer Ingelheim India has signed a Memorandum of Understanding (MoU) with Hyderabad-based EMRI Green Health Services a GVK enterprise, the operator of the ...

Boehringer Ingelheim's schizophrenia drug candidate has failed in clinical trials, leading to the discontinuation of further research. Global pharmaceutical company Boehringer Ingelheim noted on ...

Boehringer Ingelheim, is a biopharmaceutical company active in both human and animal health, announced that the company is adding an innovative preclinical programme with the acquisition of Nerio ...

Boehringer Ingelheim announced it will buy Nerio Therapeutics for $1.3 billion Monday morning. The German drugmaker is bolstering its immuno-oncology pipeline by adding the San Diego-based drug ...

WASHINGTON — A federal judge ruled against Boehringer Ingelheim’s challenge to the new Medicare drug price negotiation program, handing the pharmaceutical industry its latest in a string of ...

Boehringer Ingelheim, one of the world’s largest pharmaceutical companies, announced a new partnership in China on Monday, and remains upbeat about the market amid strains between Beijing and ...

As one of Boehringer Ingelheim's asthma competitors catches scrutiny over pricing and access concerns, the company itself is taking steps to cut patient costs in the U.S. The German drugmaker will ...